Ganitumab
Based on 1 publication(s) in Google Scholar
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.
For research use only. We do not sell to patients.
- Purity: 96.00%
- CAS No.: 905703-97-1
- Molecular Weight:145.743 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ganitumab
More
Biological Activity
Human IgG1 kappa
Human
IGF1R/CD221
Ganitumab (AMG 479; 0.032-500 nM; 10 min; CT26 cells) binds mIGF1R and inhibits IGF1- and IGF2-mediated activation of mIGF1R[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CT26 cells
-
Concentration:0.032-500 nM
-
Incubation Time:10 minutes
-
Result:Inhibited IGF1-induced autophosphorylation of mIGF1R in CT26 murine colon carcinoma cells in a dose-dependent manner.
Ganitumab (300 μg/dose; i.p.; female athymic nude mice) reduces peripheral blood neutrophils[1].
Ganitumab (300 μg/dose; i.p.; male athymic nude mice) causes impaired glucose tolerance in male mice and increases serum levels of mGH, mIGF1 and mIGFBP3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Naïve and tumor-bearing mice[1]
-
Dosage:1 mg/dose
-
Administration:Intraperitoneal injection
-
Result:Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth.
-
Animal Model:Male athymic nude mice[1]
-
Dosage:300 μg/dose
-
Administration:Intraperitoneal injection, twice per week for a total of five doses
-
Result:Had significantly higher serum glucose levels than hIgG1-pretreated mice.
Increased serum levels of mIGF1, mIGFPB3 and mGH.
-
Animal Model:Female athymic nude mice[1]
-
Dosage:300 μg/dose
-
Administration:Intraperitoneal injection, twice per week for a total of five doses
-
Result:Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 MCF-7 cells with Ganitumab (HY-P99294, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control. -
Loaded Ganitumab on AHC2 biosensor, can bind IGF-I R Protein, Human (HEK293, His-Avi, HY-P78458) with an affinity constant of 8.072E-10 M as determined in BLI assay.
Chemical Information
-
CAS No. 905703-97-1
-
Appearance Liquid
-
Molecular Weight 145.743 kDa
-
Color Colorless to light yellow
-
SMILES
[Ganitumab]
-
Synonyms
AMG 479; Human Anti-IGF1R Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)